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Few issues in medical academia are as ethically pertinent and emotionally charged as assisted dying and its legal regulation. Observers worldwide are closely scrutinizing 
developments in Belgium and the Netherlands, where euthana-
sia (defined in legal and scientific terms as lethal drug adminis-
tration at the explicit request of the patient) and assisted suicide 
have been regulated since 2002 and where, among other 
research, repeated population-based surveys monitor develop-
ments and inform the ongoing debate.1–7 These surveys report 
prevalence and characteristics of end-of-life practices. These 
practices include a wide array of acts potentially influencing 
time of death in addition to euthanasia, such as the administra-
tion of drugs with the explicit intention to hasten death without 
the patient’s explicit request, or “life-ending acts without 
explicit patient request.”
These acts are often understood as physician-initiated non-
voluntary or involuntary termination of life. They feature prom-
inently in debates over assisted dying and are regarded as an 
indicator of the ineffectiveness of safeguards for legal euthanasia 
and a slippery slope to undesirable practices.8,9 Studies have 
found that although the legalization of assisted death was fol-
lowed by a reduction in the occurrence of these acts, it did not 
put an end to the practice.6,7 In addition, although these acts 
occur in nonpermissive countries,2,10–12 their rate in Belgium 
remains higher than elsewhere.2,4–6,10–12
Little attention has been paid to the characteristics of cases 
in which life has been ended without explicit patient request. A 
previous publication comparing cases of euthanasia and life-
ending acts without explicit patient request in Belgium identi-
fied important differences in terms of decision-making and 
drugs used. Life-ending acts without explicit patient request 
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Background: “Life-ending acts without explicit patient request,” as identified in robust international studies, are central in current 
debates on physician-assisted dying. Despite their contentiousness, little attention has been paid to their actual characteristics and to 
what extent they truly represent nonvoluntary termination of life.
Methods: We analyzed the 66 cases of life-ending acts without explicit patient request identified in a large-scale survey of physicians 
certifying a representative sample of deaths (n = 6927) in Flanders, Belgium, in 2007. The characteristics we studied included physi-
cians’ labelling of the act, treatment course and doses used, and patient involvement in the decision.
Results: In most cases (87.9%), physicians labelled their acts in terms of symptom treatment rather than in terms of ending life. By 
comparing drug combinations and doses of opioids used, we found that the life-ending acts were similar to intensified pain and symp-
tom treatment and were distinct from euthanasia. In 45 cases, there was at least 1 characteristic inconsistent with the common 
understanding of the practice: either patients had previously expressed a wish for ending life (16/66, 24.4%), physicians reported that 
the administered doses had not been higher than necessary to relieve suffering (22/66, 33.3%), or both (7/66, 10.6%).
Interpretation: Most of the cases we studied did not fit the label of “nonvoluntary life-ending” for at least 1 of the following reasons: 
the drugs were administered with a focus on symptom control; a hastened death was highly unlikely; or the act was taken in accor-
dance with the patient’s previously expressed wishes. Thus, we recommend a more nuanced view of life-ending acts without explicit 
patient request in the debate on physician-assisted dying.
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predominantly involved the use of opioids, which are rarely 
used in euthanasia, and life-shortening was often estimated at 
less than 24 hours by physicians.5 These findings raised ques-
tions about whether these acts are truly equivalent to nonvolun-
tary termination of life. With several countries including Can-
ada, Australia and the United Kingdom bringing the debate 
over assisted death to legislative levels, in-depth analysis of the 
practices surrounding these acts is of immediate relevance.
Our aim is to revisit in detail the cases in which these acts 
were identified in a representative mail survey of physicians 
certifying 6927 deaths in Belgium in 200713 to determine to 
what extent these cases represent nonvoluntary termination of 
life. We examined the relevant survey data on the terms physi-
cians used to denote their acts, the characteristics of drugs and 
doses used, and the patients’ involvement in decision-making.
Methods
Study design
In 2007, we conducted a large-scale death certificate survey in 
Flanders, the semiautonomous northern half of Belgium with 
a population of about 6 million people and 55 000 deaths per 
year. Between June and November, we drew a sample of 6927 
deaths from the Flemish Agency for Care and Health, with 
disproportionate stratification into 4 strata based on cause of 
death and the corresponding likelihood of an end-of-life deci-
sion potentially hastening death. This stratification was used 
to capture more cases with end-of-life decisions for statistical 
power: we sampled 100% of deaths with euthanasia desig-
nated as cause of death on the death certificate (in free text or 
classified as Z41 using the International Statistical Classifica-
tion of Diseases and Related Health Problems, 10th revision), 
50% of malignancy deaths (ICD-10 code C), 25% of deaths 
classified with ICD-10 codes E,F,G,J,K or N, and 12.5% of 
deaths with any other cause of death.
We sent a 5-page questionnaire on end-of-life decisions 
and practices to the certifying physicians, along with a letter 
explaining the study, with a maximum of 3 reminders and a 
nonresponse questionnaire in case no response was received. 
Response was regarded as implicit consent to participate. 
The study protocol and rigorous mailing procedure involving 
a lawyer as intermediary between physicians and researchers 
guaranteed total anonymity for participating physicians and 
their patients and was approved by the Ethical Review Boards 
of the University Hospitals of the Vrije Universiteit Brussels 
and Ghent University, and endorsed by the Belgian Medical 
Disciplinary Board and the Belgian Federal Privacy Commis-
sion. Information from the death certificates on sex, age, 
place of death and cause of death was encoded by the Agency 
for Care and Health to preclude any identification of patients 
or physicians. The survey methods have been detailed in a 
protocol paper.13
Questionnaire
The questionnaire was extensively validated in previous studies 
in Belgium and other European countries,1–7 and again for the 
present study. We identified cases of “life-ending acts without 
explicit request” as in previous studies:1–7,11,12 an affirmative 
response to the question “Was the death the consequence of 
the use of drugs prescribed, supplied or administered by you or 
another physician with the explicit intention of hastening the 
end of life or of enabling the patient to end their own life?” 
and a negative response to the question “Was the decision 
made after an explicit request by the patient?” Additional ques-
tions (Appendix 1, www.cmajopen.ca/content /2/4/E262/suppl 
/DC1) dealt with the drugs and doses used for the act, charac-
teristics of treatment in the patient’s final days, whether the 
patient had at some point expressed a wish for life to be ended 
(implicitly or explicitly, but not as a formal euthanasia request), 
and the term that best described the act according to the physi-
cians themselves (we presented a list of predetermined options 
with one open category of “other”).
Data collection
We performed a detailed case-by-case review of physician-
reported characteristics of drug treatment and patient involve-
ment. To determine whether the opioid doses were higher 
than necessary to relieve symptoms, we used the judgment of 
the physician completing the survey. We defined low-dose 
benzodiazepines as any dose of lorazepam less than or equal to 
2.5 mg, diazepam less than or equal to 20 mg (or no dose 
indicated) or midazolam less than or equal to 2 mg. We 
defined high-dose benzodiazepines as more than 2.5 mg 
lorazepam or more than 2 mg (or no dose indicated) mid-
azolam. We classified high-dose benzodiazepines, propofol 
and barbiturates as “strong sedatives.” We determined that a 
patient did not have a life-ending act if he or she had received 
opioid doses no higher than necessary for symptom control 
and only low-dose benzodiazepines. We determined that a 
patient had a life-ending act performed if he or she received 
opioid doses higher than necessary for symptom control, with 
or without strong sedatives. For unknown drug doses, we 
ascribed a lethal potential to short-acting midazolam, but not 
to diazepam because of its long and delayed action.
Statistical analysis
We chose not to weight cases for the disproportionate strati-
fication and nonresponse, because our aim was to describe 
the raw cases captured in the survey and not to present them 
as representative for all deaths via life-ending act without 
explicit patient request, and a comparison of analyses using 
unweighted and weighted data showed no significant differ-
ences (Appendix 2, www.cmajopen.ca/content/2/4/E262 
/suppl /DC1). We used χ2 to determine the significance (p < 
0.05) of differences between end-of-life practices. We used 
SPSS 22.0 to perform all analyses.
Results
We received responses for 3623 of the 6927 deaths sampled, 
for a response rate of 58.4%. From these responses, we identi-
fied 66 cases of life-ending acts without explicit patient request 
(Table 1). The nonresponse survey identified 725 cases for 
which a response was not possible (physician was unable to 
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identify the patient or unable to retrieve the patient file; treat-
ing physician could not be reached).
We identified the terms best describing the acts according 
to the reporting physicians. The options “palliative sedation” 
(68.2%) and “symptom treatment” (19.7%) were selected 
most often, whereas “compassionate life-ending” was chosen 
in 6.1% of cases (Table 2). “Euthanasia” was never selected.
We compared cases of life-ending acts without explicit 
patient request with cases of euthanasia and the intensified 
alleviation of pain or symptoms (taking into account possible 
life-shortening) with respect to the drugs and opioid doses 
administered in the patient’s final 24 hours (Table 3). Data for 
doses was missing for many cases; however, we did find signifi-
cant differences between life-ending acts without explicit 
patient request and euthanasia in terms of drugs used. Drugs 
other than opioids were used more often in euthanasia than in 
life-ending acts without explicit patient request (59.7% v. 
6.1%, p < 0.001; Table 3). When opioids were used in eutha-
nasia, the dose was generally higher than that used in the life-
ending acts without explicit patient request (p = 0.04; Table 3). 
We found no significant differences between life-ending acts 
without explicit patient request and intensified alleviation of 
pain and other symptoms in terms of the combinations of 
drugs used (p = 0.2) or doses (p  = 0.9) (Table 3). In both prac-
tices, opioids were used in more than 90% of cases (Table 3).
Of the 66 cases we identified, the doses of opioids adminis-
tered in 29 cases (43.9%) were reported by the attending phy-
sician to be no higher than necessary to relieve symptoms, with 
or without low-dose benzodiazepines (Table 4). In another 15 
cases (22.7%), opioids were administered in doses reportedly 
higher than necessary to relieve symptoms (Table 4). In 20 
cases (30.3%), the patients were given strong sedatives (Table 
4). In 23 cases (34.8%), patients had explicitly or implicitly 
expressed a wish for life-ending at some point (Table 4). In 45 
cases (68.2%), the act had at least 1 characteristic that is incon-
sistent with the common understanding of the practice of life-
ending acts without explicit patient request: either physicians 
administered doses that were no higher than necessary for 
symptom control (n = 22 patients among those who had not 
expressed a wish to end life), patients had expressed a wish to 
end their life (n = 16 patients among those who received drugs 
not normally used as part of mainstream palliative care) or 
both (n = 7) (Table 4).
Interpretation
In most cases, physicians reporting life-ending acts without 
explicit patient request did not label their acts in terms of life-
ending, but rather in terms of symptom treatment. A compar-
ison of drug combinations and opioid doses used showed 
these acts to be similar to intensified pain and 
symptom treatment and significantly distinct from 
euthanasia. Finally, in 68.1% of cases, the physi-
cian did not perform a life-ending act without 
request, either because they did not administer 
medication in a dose that was higher than neces-
sary for symptom control, or because the patient 
had expressed a wish to end their life, or both.
This study elaborates on the results of previous 
studies5,18,19 that have shown that the medications 
provided in life-ending acts without explicit 
patient request are significantly different from 
those provided in euthanasia and similar to those 
provided in standard palliative care. In addition, 
the terminology used by physicians suggests that 
their focus was not on hastening death, and other 
studies have presented similar results.18–21 Finally, 
the use of stable or slowly increasing doses of opi-
oids no higher than necessary for symptom con-
Table 2: Term used for life-ending acts without 
explicit patient consent by physicians
Term
No. (%) 
n = 66
Symptom treatment 13 (19.7)
Palliative sedation 45 (68.2)
Compassionate life-ending 4 (6.1)
Euthanasia 0 (0.0)
Other 4 (6.1)
Table 1: Characteristics of physicians and patients involved in 
life-ending acts without explicit patient request
Characteristic
No. (%) 
n = 66
Physician specialty
Family physician 33 (50.0)
Specialist 33 (50.0)
Patient age, yr
1–64 10 (15.2)
65–79 28 (42.4)
≥ 80 28 (42.4)
Patient sex
Male 34 (51.5)
Female 32 (48.5)
Patient cause of death (as listed on death certificate)
Cancer 41 (62.1)
Cardiovascular disease 
(including cerebrovascular accident)
10 (15.2)
Respiratory disease 5 (7.6)
Neurological disease 3 (4.5)
Other disease 7 (10.6)
Patient place of death
Home 22 (33.3)
Hospital 32 (48.5)
Nursing home 11 (16.7)
Other 1 (1.5)
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trol makes it unlikely that death was actually hastened in 
many cases. Several previous studies have reported that even 
high-dose opioids are most often ineffective at hastening 
death, especially when doses are proportionate to the severity 
of a patient’s symptoms.14,22–29
How can the contradiction between intention and act be 
explained? Many physicians continue to believe that opioids 
hasten death at even moderate doses and feel that adequate 
symptom treatment would concomitantly hasten the patient’s 
death (if only by a small amount of time).5,30 Furthermore, a 
physicians’ interpretation of “explicit intention” may be sub-
jective or semantic — they may have meant “partial intention” 
or hope that the patient would pass on quickly and comfort-
ably. Previous studies have already put forward this idea and 
the idea that some medical cultures may be more inclined to 
admitting so than others.31,32
Although the perception of these acts as the nonvoluntary 
termination of life is mitigated by our results, some ethical 
ambiguities remain inherent to the practice. Although the 
chosen treatment course often entailed no ill effects (i.e., com-
fort was in all likelihood achieved without hastening death, 
which is standard practice and preferable to forgoing effective 
treatment) and patients dying in discomfort, an explicit intent 
to hasten death in the absence of the patient’s request is in 
itself objectionable, regardless of the outcome. In addition, 
amid active debate on the proper balance between respecting 
autonomy and paternalism in medicine,33 whether an implicit 
or explicit wish to end life, supposing it is regarded as a suffi-
cient exertion of autonomy, can be acted upon is not straight-
forward. Such a wish cannot be ascribed the same legal weight 
as a formal request for euthanasia, but some physicians may 
see it as an important indication, in the absence of others, of 
the patient’s preferences.
Strengths and limitations
We used robust source data obtained with rigorous methods 
that guaranteed anonymity and produced a reasonable 
response rate despite the medicolegal sensitivity of the sub-
ject.6,13 However, we cannot exclude some degree of nonre-
sponse bias. Desirability biases in the source data are possi-
ble; despite strict anonymity, some physicians may not have 
reported life-ending acts without explicit patient request in 
the survey. Only the physicians’ perspectives were studied. 
In addition, surveys are inevitably reductionist, and cannot 
fully capture the complexity and diversity of clinical cases 
and doctor–patient interactions at the end of life. Providing 
an options list for the term that best described physicians’ 
acts may have introduced bias, though there was the possi-
bility of a free text answer. Finally, we cannot exclude the 
possibility of poor recall in physicians’ reporting, particularly 
of drugs and doses where missing data may have biased the 
results.
Table 3: Comparison of physician-reported drugs and doses used in end-of-life care*
Drugs and doses used†
Intensified alleviation 
of pain and other 
symptoms, 
No. (%)
n = 1249
Life-ending act 
without explicit 
patient request,  
No. (%)
n = 66
Euthanasia or 
assisted suicide, 
No. (%)
n = 142
Drugs n = 1199 n = 65 n = 139
Opioids 1 139 (95.0) 61 (93.8) 56 (40.3)
As the only drug    703 (58.6) 29 (44.6) 22 (15.8)
With benzodiazepines    284 (23.7) 17 (26.2) 20 (14.4)
With drugs other than 
benzodiazepines
     78   (6.5)   8 (12.3)   3   (2.1)
With benzodiazepines and other drugs      74   (6.2)   7 (10.8) 11   (7.9)
No opioids      60   (5.0)   4   (6.1) 83 (59.7)
χ2 p value 0.2 < 0.001
Reported OME opioid doses used in 
last 24h‡, mg
n = 821 n = 37 n = 44
1–119    307 (37.4) 14 (37.8)  6  (13.6)
120–239    267 (32.5) 10 (27.0) 10 (22.7)
240–479    179  (21.8) 10 (27.0) 21 (47.7)
≥ 480      68   (8.3)   3  (8.1)  7 (15.9)
χ2 p value 0.9 0.04
Note: OME = oral morphine equivalent. 
*Administration of drugs for the treatment and management of pain or other symptoms, taking into account a potential life-shortening effect. 
†Cases with missing values were excluded from the analysis. 
‡Conversion rates were obtained from handbooks and review publications with equianalgesic tables.14–17
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Conclusions and recommendations for research, 
practice and policy
Our analysis challenges the perception that life-ending acts 
without explicit patient request are equivalent to nonvolun-
tary termination of life. Many of the acts identified in our sur-
vey were either in accordance with a patient’s wish to die 
(albeit not in the form of a legally prescribed euthanasia 
request) or without actual life-terminating effect. A more 
nuanced view of these acts is warranted in the debate over 
assisted death.
Our findings further suggest that physicians might benefit 
from education on standards of decision-making and the 
effects of high-dose opioids in terms of life-shortening poten-
tial. Such knowledge would contribute to achieving both ethi-
cally coherent and clinically effective end-of-life practice.
To better understand the wishes of patients regarding 
assisted death and the responses of physicians to these wishes, 
we propose complementary research as part of prospective 
studies on advance care planning. To explore the consider-
ations and motivations of all stakeholders, and to better dis-
tinguish life-ending acts without explicit patient request from 
uncontroversial practices, in-depth interviews with physi-
cians, nurses, patients and relatives are worthwhile.18 Cross-
national vignette studies on end-of-life practices should help 
establish whether clinical situations and end-of-life treat-
ments are interpreted or labelled differently across countries 
and medical cultures.
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